Global Blood Therapeutics 관리
관리 기준 확인 4/4
Global Blood Therapeutics CEO는 Ted Love, Jun2014 에 임명되었습니다 의 임기는 8.33 년입니다. 총 연간 보상은 $ 8.19M, 8.7% 로 구성됩니다. 8.7% 급여 및 91.3% 보너스(회사 주식 및 옵션 포함). 는 $ 63.19M 가치에 해당하는 회사 주식의 1.37% 직접 소유합니다. 63.19M. 경영진과 이사회의 평균 재임 기간은 각각 6.5 년과 5.8 년입니다.
주요 정보
Ted Love
최고 경영자
US$8.2m
총 보상
| CEO 급여 비율 | 8.7% |
| CEO 임기 | 8.3yrs |
| CEO 소유권 | 1.4% |
| 경영진 평균 재임 기간 | 6.5yrs |
| 이사회 평균 재임 기간 | 5.8yrs |
최근 관리 업데이트
Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$322m |
| Mar 31 2022 | n/a | n/a | -US$310m |
| Dec 31 2021 | US$8m | US$716k | -US$303m |
| Sep 30 2021 | n/a | n/a | -US$277m |
| Jun 30 2021 | n/a | n/a | -US$266m |
| Mar 31 2021 | n/a | n/a | -US$249m |
| Dec 31 2020 | US$18m | US$661k | -US$248m |
| Sep 30 2020 | n/a | n/a | -US$282m |
| Jun 30 2020 | n/a | n/a | -US$286m |
| Mar 31 2020 | n/a | n/a | -US$291m |
| Dec 31 2019 | US$10m | US$597k | -US$267m |
| Sep 30 2019 | n/a | n/a | -US$220m |
| Jun 30 2019 | n/a | n/a | -US$199m |
| Mar 31 2019 | n/a | n/a | -US$182m |
| Dec 31 2018 | US$10m | US$569k | -US$174m |
| Sep 30 2018 | n/a | n/a | -US$166m |
| Jun 30 2018 | n/a | n/a | -US$152m |
| Mar 31 2018 | n/a | n/a | -US$135m |
| Dec 31 2017 | US$8m | US$520k | -US$117m |
| Sep 30 2017 | n/a | n/a | -US$103m |
| Jun 30 2017 | n/a | n/a | -US$95m |
| Mar 31 2017 | n/a | n/a | -US$89m |
| Dec 31 2016 | US$1m | US$479k | -US$82m |
| Sep 30 2016 | n/a | n/a | -US$71m |
| Jun 30 2016 | n/a | n/a | -US$65m |
| Mar 31 2016 | n/a | n/a | -US$58m |
| Dec 31 2015 | US$2m | US$438k | -US$51m |
보상 대 시장: Ted 의 총 보상 ($USD 8.19M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.65M ).
보상과 수익: Ted 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Ted Love (63 yo)
8.3yrs
테뉴어
US$8,193,309
보상
Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 8.3yrs | US$8.19m | 1.37% $ 63.2m | |
| CFO & Principal Accounting Officer | 6.5yrs | US$2.76m | 0.040% $ 1.8m | |
| Chief Business & Strategy Officer | 7.5yrs | US$2.73m | 0.37% $ 17.2m | |
| Chief Commercial Officer | 4.6yrs | US$2.75m | 0.084% $ 3.9m | |
| Executive VP and Head of Research & Development | 1.4yrs | US$2.98m | 0.0089% $ 409.5k | |
| Founder & Advisor | 11.8yrs | 데이터 없음 | 데이터 없음 | |
| Founder & Advisor | 11.8yrs | 데이터 없음 | 데이터 없음 | |
| Founder & Advisor | 11.8yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Operations | 2.5yrs | 데이터 없음 | 0.062% $ 2.9m | |
| Senior Director of Corporate Communications & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & Secretary | 6yrs | US$5.93m | 0.064% $ 3.0m | |
| Senior VP & Head of Corporate Communications | 3.8yrs | 데이터 없음 | 데이터 없음 |
6.5yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: GBT 의 관리팀은 노련하고 경험 (평균 재직 기간 6.5 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 9.1yrs | US$8.19m | 1.37% $ 63.2m | |
| Lead Independent Director | 7.5yrs | US$348.28k | 0.056% $ 2.6m | |
| Independent Director | 4.8yrs | US$320.78k | 0.017% $ 783.3k | |
| Independent Director | 2.4yrs | US$313.28k | 0.013% $ 618.8k | |
| Independent Director | 6.7yrs | US$318.28k | 0.039% $ 1.8m | |
| Independent Director | 7.1yrs | US$310.78k | 0.013% $ 623.9k | |
| Independent Director | 6.8yrs | US$333.28k | 0.0098% $ 454.8k | |
| Independent Director | 3.8yrs | US$316.36k | 0.0080% $ 368.3k | |
| Advisor & Director Emeritus | less than a year | US$308.28k | 0.058% $ 2.7m | |
| Independent Director | 1.6yrs | US$735.61k | 0.0049% $ 226.5k |
5.8yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: GBT 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.